BXPLANT and ARKGEN BIOSCIONS announced on the 13th that they have signed a Memorandum of Understanding (MOU) for strategic business collaboration. Both companies plan to establish more effective development strategies and build successful pipelines throughout the biopharmaceutical development process.
BXPLANT is a scalerator specializing in preclinical and clinical development strategies and implementation, providing differentiated consulting and clinical operational solutions to new drug development companies.
ARKGEN BIOSCIONS is a company with proven expertise in genetically modified drug development, focusing on research and development of next-generation biopharmaceuticals including multi-antibody therapeutics and cancer treatment vaccines.
Collaboration Framework
Through this agreement, BXPLANT will support ARKGEN BIOSCIONS’ biopharmaceutical development by providing preclinical and clinical development strategy formulation, global regulatory compliance support, and clinical trial design and execution. ARKGEN BIOSCIONS plans to leverage BXPLANT’s expertise to pursue rapid and efficient development.
A BXPLANT representative stated, “We will provide practical support to enable biopharmaceutical development companies to achieve more successful outcomes. In particular, we plan to strengthen comprehensive development consulting, including global clinical strategies.”
An ARKGEN BIOSCIONS representative commented, “The combination of BXPLANT’s development expertise and ARKGEN BIOSCIONS’ biopharmaceutical R&D capabilities will create significant synergy.”
Both companies plan to continuously identify diverse collaboration opportunities to maximize the efficiency of new drug development and clinical operations.
source: BXPLANT and ARKGEN BIOSCIONS Sign Strategic MOU for Biopharmaceutical Development. Do-young Park. Medigate News. 2025-02-13., https://www.medigatenews.com/news/3026527850
